Loyal, based in San Francisco, develops drugs intended to extend the healthy lifespan of dogs, led by LOY-002 for senior dogs. It raised a $100 million Series C led by age1 in February 2026, taking total funding past $250 million.
At a glance
| Price from | Not public |
| Best for | Vets and owners of senior and large dogs |
From Loyal's own website.
What stands out
- Furthest along the regulatory path
- Shorter dog lifespans allow faster proof
Worth knowing
- Not yet approved for sale
- Animal health only
How it ranks
Loyal is ranked 4th of 10 in Best Longevity Startups (Lister Score 93.1).
#4 in Best Longevity Startups · Lister Score 93.1
In January 2026 the FDA accepted the target animal safety section of LOY-002's conditional approval application, the second of three major parts..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does Loyal rank on Lister?
Loyal is ranked 4th of 10 in Best Longevity Startups (Lister Score 93.1).
Appears in
Add this badge to your site
If you work at Loyal, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.